BioSpace News Archive

ANGLE plc, a world-leading liquid biopsy company, is pleased to announce it has signed a distribution agreement with Promedeus s.r.o to enable and support the roll out of the FDA cleared and CE marked Parsortix® PC1 system across the Czech Republic for its intended use in metastatic breast cancer.

Immunovia AB announced positive feedback from its physician experience program for the IMMray™ PanCan-d test in the U.S., which is nearing completion.

Phonak, a leading global provider of life-changing hearing solutions, announces that Oliver Frank will be taking up the position as Vice President Phonak Marketing effective December 1, 2022.

Ryvu Therapeutics announced that it will present clinical data on RVU120 in relapsed/refractory metastatic or advanced solid tumors, preclinical data on RVU120 enhancing antibody-dependent cellular cytotoxicity and discovery, and optimization data on novel MTA-cooperative PRMT5 inhibitors at the AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Symposium taking place on October 26-28 in Barcelona, Spain.

Fulcrum Therapeutics, Inc announced today that new data from the open label extension (OLE) portion of the Phase 2 ReDUX4 study of losmapimod for the treatment of FSHD will be featured in a poster presentation at the World Muscle Society (WMS) Hybrid Congress taking place October 11-15 in Halifax, Canada.

Moderna, Inc. and Merck today announced that Merck has exercised its option to jointly develop and commercialize personalized cancer vaccine (PCV) mRNA-4157/V940 pursuant to the terms of its existing Collaboration and License Agreement.

Coherus BioSciences, Inc. and Shanghai Junshi Biosciences Co., Ltd (“Junshi Biosciences”, HKEX: 1877; SSE: 688180) today announced the publication of toripalimab plus chemotherapy for patients with treatment-naïve advanced non-small cell lung cancer: a multi-center randomized phase 3 trial (CHOICE-01) in the Journal of Clinical Oncology.

RenBio today announced that it has received a $2.0 million grant from the Empire State Development’s (ESD) New York State Biodefense Commercialization Fund for its proposal, “Rapid Delivery of Monoclonal Antibodies for the Prevention of Future Infectious Disease Outbreaks.”

Theriva Biologics, Inc., is the new name of Synthetic Biologics, Inc. The new name, logo and branding elements were introduced to better reflect Theriva’s position as a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus platform to address devastating cancers with high unmet need.

Amolyt Pharma, a global company specialized in developing therapeutic peptides for rare endocrine and related diseases, today announced positive results from the second patient cohort in its Phase 2a clinical proof of concept trial of AZP-3601, a PTH1 receptor agonist, which the company is developing as a potential treatment for hypoparathyroidism.